Show/Hide Menu

Engineering the medicines 
of tomorrow

Learn how MorphoSys approaches drug development.

More Info

Hematological cancers 
affect adults and children alike.

MorphoSys is developing several blood cancer programs.

More Info

Antibody drugs have transformed the way 
inflammatory and autoimmune diseases are treated today.

MorphoSys is exploring new approaches to continue this success.

More Info

Solid tumors can occur in 
several organs of the human body.

MorphoSys and its partners are working on a broad portfolio of new therapies.

More Info

MorphoSys's vision

MorphoSys is committed to developing exceptional new treatments for patients suffering from serious diseases. A leader in the field of therapeutic antibodies today, MorphoSys is driven by the ambition of creating the most valuable pipeline of biopharmaceuticals in the biotechnology industry.

learn more about the company

12/01/2017
MorphoSys Partner to Start Phase 2 Trial with Bimagrumab in Obese Patients...
05/01/2017
Dr. Malte Peters to become new Chief Development Officer of MorphoSys AG
03/01/2017
MorphoSys to Present at Upcoming Investor Conferences
13/12/2016
MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in...
06/12/2016
MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202...
06/12/2016
MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208...
28/11/2016
MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing...
17/11/2016
MorphoSys Announces That Its Licensee Janssen Has Submitted Biologics...
15/11/2016
MorphoSys Raises EUR 115 million in Private Placement
15/11/2016
MorphoSys to Raise Capital via a Private Placement of New Shares

January 17, 2017
Kepler Cheuvreux German Corporate Conference
Frankfurt, Germany

conferences

Therapeutic pipeline

MorphoSys has established one of the broadest pipelines in the biopharmaceutical industry.
Pipeline

Media and investors

MorphoSys is driven by the ambition to create the most valuable pipeline of biopharmaceuticals in the industry.
Media and investors

Partnering opportunities

Collaborations are a main component of our strategy. We are open to discuss deal structures where we can contribute to the development of novel drugs in a significant way.
Partnering opportunities

Drug development capabilities

MorphoSys is dedicated to become a fully integrated biopharmaceutical company including late stage clinical development and marketing/co-promotion of its own drugs.
Drug development capabilities

Leading antibody technologies

MorphoSys has made HuCAL and its successor technology Ylanthia into reliable sources of therapeutic antibody candidates.
Leading Antibody Technologies

Proprietary program MOR208

When blood formation leads to cancer: the CD19-antibody MOR208 is currently being evaluated in ALL, CLL and NHL.
MOR208

Antibody backgrounder

Antibodies are essential to life. Today, these molecules are used as therapeutic agents for the treatment of severe diseases.
Antibody Backgrounder

Proprietary program MOR209

Together with Emergent BioSolutions, MorphoSys is developing a new way to fight prostate cancer.
MOR209

Lighthouse project Gantenerumab

Is being developed by Roche for Alzheimer´s desease.
Gantenerumab